A new research study whose outcomes were published in the International Journal of Antimicrobial Agents has discovered early evidence that the mix of hydroxychloroquine, a popular anti-malaria drug understood under the brand name Plaqenuil, and antibiotic azithromycin (aka Zithromax or Azithrocin) might be especially efficient in dealing with the COVID-19 coronavirus and decreasing the period of the infection in clients.
The researchers carried out a research study on 30 validated COVID-19 clients, treating each with either hydroxychloroquine on its own, a mix of the medication with the antibiotic, as well as a control group that got neither. The research study was conducted after reports from treatment of Chinese clients suggested that this particular combination had effectiveness in shortening the period of infection in patients.
The patient mix included in the research study consisted of 6 who showed no symptoms whatsoever, along with 22 who had symptoms in their upper breathing system (things like sneezing, headaches and sore throats, and 8 who showed lower respiratory system symptoms (primarily coughing). 20 of the 30 participants in the study got treatment, and the results showed that while hydroxycholoroquine worked on its own as a treatment, when combined with azithromycin it was much more effective, and by a substantial margin.
These results represent a restricted research study with a small number of patients, however they are promising, especially when combined with earlier reports from clients in China with the very same treatment alternatives. Scientist internationally are testing a variety of possible treatments, consisting of a series of drugs used previously in the efforts to combat Ebola, SARS, HIV and other international break outs.
There are no confirmed effective treatments particularly for COVID-19 to date, however regulators and medical researchers everywhere are striving to get through the process of testing and approvals searching for something that can at least decrease the period or seriousness of symptoms in patents. Vaccine development is likewise underway, but any authorized and efficient COVID-19 vaccine is at least 12-18 months away, even with resources redirected towards establishing one as fast as is security possible.